JZ-4109

JZ-4109 (Compound 3) (0.76 nM-1.56 μM;30 min) potently inhibits wild-type recombinant GCase with an IC₅₀ of 8 nM via linear mixed inhibition^[1].
JZ-4109 (0.25-100 μM; heated from 20 °C to 95 °C at 0.1 °C/s) stabilizes wild-type recombinant GCase against thermal denaturation^[1].
JZ-4109 (0.2-2 μM; 3 days) significantly increases GCase protein abundance and enzyme activity in healthy control human fibroblast cells without altering GBA mRNA levels^[1].
JZ-4109 (2 μM; 3 days) promotes maturation and trafficking of GCase to post-ER compartments in healthy control human fibroblast cells without increasing ER-retained GCase^[1].
JZ-4109 (2 μM; 3 days) significantly increases GCase abundance and enzyme activity in lysosomal fractions of HEK cells^[1].
JZ-4109 (0.2-2 μM; 3 days) significantly increases mature post-ER GCase protein abundance and enzyme activity in homozygous GBA^N370S mutant human fibroblast cells from a type-1 Gaucher’s disease donor^[1].
JZ-4109 (4.12-33.0 μM, co-incubated with 16.5 μM GCase) induces dose-dependent dimerization of wild-type GCase in solution^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.